Sarcopenia Models and Efficacy Services

Anti-Tumor Drug Efficacy Evaluation
Humanized Immune Checkpoint Mouse Models and Efficacy Services
Autoimmune Disease Efficacy Evaluation
Autoimmune Nephropathy Models and Efficacy ServicesAsthma Models and Efficacy ServicesSystemic Lupus Erythematosus (SLE) Models and Efficacy ServicesSjögren's Syndrome Models and Efficacy ServicesNeuroimmune Diseases Models and Efficacy ServicesAutoimmune Dermatoses Models and Efficacy ServicesInflammatory Bowel Disease (IBD) Models and Efficacy ServicesRheumatoid Arthritis (RA) Models and Efficacy ServicesImmune Reconstitution Autoimmune Disease Models and Efficacy Services
Metabolic Disease Efficacy Evaluation
Obesity Models and Efficacy ServicesType II Diabetes Models and Efficacy ServiceType I Diabetes Models and Efficacy ServicesAndrogenetic Alopecia (AGA) Models and Efficacy ServicesMASH Models and Efficacy ServicesChronic Liver Fibrosis Models and Efficacy ServicesAcute Liver Injury Models and Efficacy ServicesCholestasis Models and Efficacy ServicesAlcohol-related Liver Disease (ALD) Models and Efficacy ServicesChronic Kindey Disease (CKD) Models and Efficacy ServicesActue Kindey Disease (AKD) Models and Efficacy ServicesDiabetes Nephropathy (Diabetic Kidney Disease) Models and Efficacy ServicesSarcopenia Models and Efficacy ServicesGout/Hyperuricemia Models and Efficacy ServicesFemale Reproduction Models and Efficacy Services
Neurological Disease Efficacy Evaluation
Behavioral AnalysisIn Vivo Drug Efficacy EvaluationDelivering Therapeutics Across the Blood-Brain Barrier (BBB)Parkinson’s Disease Rat Model
Cardiovascular Diseases Efficacy Evaluation
Heart Failure Models and Efficacy ServicesHypertension Models and Efficacy ServicesAtherosclerosis Models and Efficacy ServicesAdvanced Cardiovascular and Metabolic Complication Models and Efficacy ServicesHyperlipidemia Models and Efficacy ServicesHypertropic Cardiomyopathy Models and Efficacy ServicesStroke Models and Efficacy ServicesThrombosis Models and Efficacy Services
Infectious Disease Efficacy Evaluation
About Our Biosafety LaboratoryIn vitro Drug Efficacy EvaluationIn vivo Drug Dfficacy Evaluation
Respiratory Disease Efficacy Evaluation
Acute Lung Injury (ALI) ModelsIdiopathic Pulmonary Fibrosis (IPF) ModelsChronic Obstructive Pulmonary Disease (COPD) ModelsBronchiectasis ModelsPulmonary Function Test
Disease Rat Models
60% HFD Induced DIO Rat ModelsHFHSD+STZ Induced Type II Diabetes Model in SD Rat45％HFHS+STZ Induced Type I Diabetes Models in SD RatCDAHFD-induced Rat MASH ModelCCL4-induced Chronic Liver Fibrosis Models in SD Rat5/6 Nephrectomy-induced Rat CKD ModelAdenine-induced Rat CKD ModelOVX-induced Rat Osteoporosis Model2K1C-induced Hypertension Model in SD RatMCAO-induced CIS Model in SD Rat
Bioanalytical Services
Phenotyping Services
Oncology PlatformMetabolism PlatformEfficacy and Pathology Platform
Non-GLP Toxicity Assessment Services
Cell Therapy & Gene Therapy Efficacy Evaluation

Sarcopenia is defined as the progressive loss of muscle mass and function resulting from aging. This condition is associated with increased incidence of falls and injuries, cardiac disease, respiratory disease, and cognitive impairment, and is closely linked to frailty, poor quality of life, and increased mortality. So far, there is no FDA approved pharmacological therapy for sarcopenia. Currently, pre-clinical animal models could be divided into four types: (1) aged animals; (2) genetically modified animals; (3) intervention models; (4) induced disuse models.


GemPharmatech has developed several sarcopenia mouse models, including a dexamethasone -induced sarcopenia model, CVMD related cachexia-induced sarcopenia model, and MSTN over-expression induced sarcopenia model.


1. Dexamethasone-induced sarcopenia model


(1) Dexamethasone treatment slightly affected body weight, but significantly decreased lean mass of B6J mice


1.png

2.png

Figure 1. The growth curve of the animals during the study period and the body composition of animals 14 days post 1st Dexamethasone injection. Data were presented as Mean±SD, N=6~8, ****, p < 0.0001 by one-way ANOVA with Dunnett’s pot-hoc test.


(2) Dexamethasone treatment decreases exercise performance of C57Bl/6JGpt mice


3.png

Figure 2. Exercise performance of Vehicle or Dexamethasone treated animals was measured by treadmill. Data presented as Mean±SD, N=6~8, *, p < 0.05 by one-way ANOVA with Dunnett’s pot-hoc test.

TALK WITH OUR EXPERTS

GemPharmatech is committed to protecting and respecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please click below to say how you would like us to contact you:

In order to provide you with the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please click the checkbox below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.